4
H index
1
i10 index
37
Citations
Office of Health Economics | 4 H index 1 i10 index 37 Citations RESEARCH PRODUCTION: 1 Articles 25 Papers 1 Books RESEARCH ACTIVITY:
MORE DETAILS IN: ABOUT THIS REPORT:
|
Works with: Authors registered in RePEc who have co-authored more than one work in the last five years with Martina Garau. | Is cited by: | Cites to: |
Working Papers Series with more than one paper published | # docs |
---|---|
Consulting Reports / Office of Health Economics | 13 |
Research Papers / Office of Health Economics | 7 |
Briefings / Office of Health Economics | 4 |
Year | Title of citing document | |
---|---|---|
2020 | A Multinational European Study of Patient Preferences for Novel Diagnostics to Manage Antimicrobial Resistance. (2020). Mott, David ; Hopkins, Michael M ; Mestre-Ferrandiz, Jorge ; Llewelyn, Martin J ; Hampson, Grace. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00516-0. Full description at Econpapers || Download paper | |
2020 | HTA methodology and value frameworks for evaluation and policy making for cell and gene therapies. (2020). Shah, Koonal ; Graf von der Schulenburg, Johann ; Shen, Jie ; Durand-Zaleski, Isabelle ; Ratcliffe, Mark ; Coyle, Doug ; Pemberton-Whiteley, Zack ; Palmer, Stephen ; Moutie, Anne-Sophie ; Meunier, Aurelie ; Longworth, Louise ; Greiner, Wolfgang ; Zhao, Kun ; Garrison, Louis ; Sproule, Doug ; Farrington, Jasmine. In: The European Journal of Health Economics. RePEc:spr:eujhec:v:21:y:2020:i:9:d:10.1007_s10198-020-01212-w. Full description at Econpapers || Download 2020 | Multiple Criteria Decision Analysis for HTA across four EU Member States: Piloting the Advance Value Framework. (2020). Molina-Lopez, T ; Montibeller, G ; Linch, M ; Angelis, A ; Kanavos, P ; Espin, J ; Arickx, F ; Orzel, K ; Zawada, A. In: Social Science & Medicine. RePEc:eee:socmed:v:246:y:2020:i:c:s0277953619305908. Full description at Econpapers || Download paper |
2020 | Price Models for Multi-indication Drugs: A Systematic Review. (2020). Trapero-Bertran, Marta ; Segu-Tolsa, Jose Luis ; Puig-Junoy, Jaume ; Campillo-Artero, Carlos. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:1:d:10.1007_s40258-019-00517-z. Full description at Econpapers || Download paper | |
2020 | Value-Based Pricing Alternatives for Personalised Drugs: Implications of Asymmetric Information and Competition. (2020). Pertile, Paolo ; LEVAGGI, ROSELLA. In: Applied Health Economics and Health Policy. RePEc:spr:aphecp:v:18:y:2020:i:3:d:10.1007_s40258-019-00541-z. Full description at Econpapers || Download paper |
Year | Title | Type | Cited |
---|---|---|---|
2009 | Access Mechanisms for Orphan Drugs: A Comparative Study of Selected European Countries In: Briefings. [Full Text][Citation analysis] | paper | 6 |
2007 | Estimating Pharmaceutical Companies Value to the Nation: Case Study of the British Pharma Group In: Briefings. [Full Text][Citation analysis] | paper | 0 |
2018 | Multi-Indication Pricing (MIP): Practical Solutions and Steps to Move Forward In: Briefings. [Full Text][Citation analysis] | paper | 2 |
2019 | How Should We Measure Quality of Life Impact in Rare Disease? Recent Learnings in Spinal Muscular Atrophy In: Briefings. [Full Text][Citation analysis] | paper | 0 |
2011 | Exploring the Interdependency between Public and Charitable Medical Research In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2010 | Assessment of the Impact of Orphan Medicinal Products on the European Economy and Society In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2009 | Assessment and Appraisal of Oncology Medicines: NICEs Approach and International HTA Experience In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2006 | Donor Investment Choices: Modeling the Value for Money of Investing in Product Development, Public Private Parnerships as Compared to Other Health Care and Non-Health Care Interventions In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2014 | Obstructive Sleep Apnoea: Health Economics Report In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2016 | Improving Efficiency and Resource Allocation in Future Cancer Care In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2017 | Policy Options for Formulary Development in Middle-income Countries: Mexico Case Study In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2017 | Policy Options for Formulary Development in Middle-income Countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2017 | Comparing Access to Orphan Medicinal Products (OMPs) in the United Kingdom and other European countries In: Consulting Reports. [Full Text][Citation analysis] | paper | 1 |
2018 | Appraising Ultra-Orphan Drugs: Is Cost-Per-QALY Appropriate? A Review of the Evidence In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2019 | Unrelieved Pain in Palliative Care in England In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2020 | Are Cost-Effectiveness Thresholds fit for Purpose for Real-World Decision Making? In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2020 | International Cost-Effectiveness Thresholds and Modifiers for HTA Decision Making In: Consulting Reports. [Full Text][Citation analysis] | paper | 0 |
2007 | European Medicines Pricing and Reimbursement: Now and the Future In: Monographs. [Full Text][Citation analysis] | book | 0 |
2011 | Pharmaceutical Pricing in Europe: Is Differential Pricing a Win-Win Solution? In: Occasional Papers. [Full Text][Citation analysis] | paper | 2 |
2013 | Exploring the link between health and wealth in decision making In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
2013 | Multi-Criteria Decision Analysis to Value Orphan Medicines In: Research Papers. [Full Text][Citation analysis] | paper | 10 |
2012 | Can and Should Value Based Pricing Be Applied to Molecular Diagnostics? In: Research Papers. [Full Text][Citation analysis] | paper | 4 |
2010 | Using QALYs in Cancer: Review of the Methodological Limitations In: Research Papers. [Full Text][Citation analysis] | paper | 8 |
2014 | Exploring the Interdependencies of Research Funders in the UK In: Research Papers. [Full Text][Citation analysis] | paper | 2 |
2016 | Applying a Multi-criteria Decision Analysis (MCDA) Approach to Elicit Stakeholders Preferences in Italy. The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL) In: Research Papers. [Full Text][Citation analysis] | paper | 0 |
2018 | Applying a Multicriteria Decision Analysis (MCDA) Approach to Elicit Stakeholders’ Preferences in Italy: The Case of Obinutuzumab for Rituximab-Refractory Indolent Non-Hodgkin Lymphoma (iNHL).(2018) In: PharmacoEconomics - Open. [Full Text][Citation analysis] This paper has another version. Agregated cites: 0 | article | |
2018 | R&D, Competition and Diffusion of Innovation in the EU: The Case of Hepatitis C In: Research Papers. [Full Text][Citation analysis] | paper | 2 |
CitEc is a RePEc service, providing citation data for Economics since 2001. Sponsored by INOMICS. Last updated March, 2 2021. Contact: CitEc Team